Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer 

Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) closed an additional $50 million tranche of a July 2025 equity private placement after achieving a clinical milestone for rondecabtagene autoleucel in the PiNACLE pivotal trial for relapsed/refractory LBCL.

The tranche was sold at $25.61 per share, bringing total placement proceeds to ~$100 million; Lyell expects cash to fund operations into Q2 2027. Smital Shah was appointed Chief Financial and Business Officer effective March 9, 2026.

Positive

• Additional $50M closed following a clinical milestone
• Total $100M equity private placement proceeds
• Purchase price $25.61 per share for the tranche
• Cash runway expected into Q2 2027
• Appointment of Smital Shah as Chief Financial and Business Officer

Negative

• Financing via private placement limits immediate public resale liquidity
• Dependence on PiNACLE milestone to trigger tranche funding
• Cash runway only into Q2 2027, indicating potential need for additional financing

News Market Reaction – LYEL

+13.54%

24 alerts

+13.54% News Effect

+17.8% Peak in 23 hr 44 min

+$70M Valuation Impact

$590M Market Cap

1.1x Rel. Volume

On the day this news was published, LYEL gained 13.54%, reflecting a significant positive market reaction. Argus tracked a peak move of +17.8% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $70M to the company's valuation, bringing the market cap to $590M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Additional tranche: $50 million Total private placement size: $100 million Purchase price per share: $25.61 +5 more

8 metrics

Additional tranche $50 million Second tranche of July 2025 equity private placement

Total private placement size $100 million Aggregate amount of equity private placement

Purchase price per share $25.61 Price for additional private placement shares

Initial closing amount $50 million Initial July 2025 closing under securities purchase agreement

Cash runway Into Q2 2027 Expected sufficiency of cash, cash equivalents and marketable securities

Treatment line Third- or later-line PiNACLE pivotal trial in relapsed/refractory LBCL

Private placement cap (historical) $100 million Up to amount from July 25, 2025 agreement

Initial price (historical) $13.32 per share Initial July 2025 private placement closing price

Market Reality Check

Price: $25.14 Vol: Volume 42,369 is below th...

low vol

$25.14 Last Close

Volume Volume 42,369 is below the 20-day average of 108,648, suggesting a relatively quiet tape pre-announcement. low

Technical Shares at $22.46 are trading above the 200-day MA of $17.46 but remain about 50% below the 52-week high of $45.

Peers on Argus

LYEL was up 1.86% with mixed peer action: AVIR appeared in momentum scans and wa...

1 Up 1 Down

LYEL was up 1.86% with mixed peer action: AVIR appeared in momentum scans and was up 1.87%, while IVVD was down 3.33%, indicating company-specific rather than broad sector-driven trading.

Previous Private placement Reports

1 past event · Latest: Jul 25 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jul 25	Private placement	Positive	+19.3%	Up to $100M equity private placement with milestone-based second tranche.

Pattern Detected

The prior private placement in July 2025 coincided with a strong positive move of 19.31%, indicating historically constructive reactions to this financing structure.

Recent Company History

This announcement follows Lyell’s July 2025 equity private placement of up to $100 million, which included an initial $50 million closing at $13.32 per share and an additional $50 million contingent on clinical milestones. That financing, tied to pivotal-stage CAR T programs including PiNACLE in large B-cell lymphoma, saw a 19.31% 24-hour share-price gain. Today’s closing of the second tranche directly reflects achievement of that milestone-linked structure and extends the previously articulated funding runway into 2027.

Historical Comparison

+19.3% avg move · In 2025, LYEL’s only prior private placement headline produced a 19.31% move, showing markets reacte...

private placement

+19.3%

Average Historical Move private placement

In 2025, LYEL’s only prior private placement headline produced a 19.31% move, showing markets reacted strongly to milestone-linked financing compared with the latest tranche closing.

Financing progressed from a July 2025 up to $100M private placement, with an initial $50M at $13.32/share and a second $50M tranche triggered upon clinical milestone achievement in the PiNACLE program.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-12-05

An effective resale registration covers 1,900,000 shares issued to ICT Holdings under a license agreement. All registered shares may be sold by ICT Holdings from time to time, and Lyell will not receive any proceeds from these sales.

Market Pulse Summary

The stock surged +13.5% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +13.5% in the session following this news. A strong positive reaction aligns with the company’s history, as the July 2025 private placement produced a 19.31% move after announcement. The latest tranche reflects a milestone hit in the PiNACLE program and extends funding into Q2 2027. Investors would still have monitored resale risk from the registered 1.9M shares and potential digestion of new equity over time.

Key Terms

equity private placement, car t-cell therapies, large b-cell lymphoma, relapsed/refractory, +3 more

7 terms

equity private placement financial

"Closing of additional $50 million tranche of $100 million equity private placement"

A private sale of a company’s shares to a small group of chosen investors rather than to the general public. Think of it as selling extra slices of a pie to a few specific buyers to raise cash quickly; it changes how big each current owner's slice is, can alter control, and signals how the company is valued, so investors watch for dilution, funding needs, and any price or governance implications.

car t-cell therapies medical

"advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies"

CAR T-cell therapies are treatments that remove a patient’s immune cells, reprogram them to recognize specific cancer markers, and return them to the body so they act like specially trained soldiers hunting tumor cells. They matter to investors because they can offer powerful, long-lasting benefits for hard-to-treat cancers but come with high development, manufacturing and regulatory costs, pricing and reimbursement uncertainty, and concentrated market risk that can drive big gains or losses.

large b-cell lymphoma medical

"rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma"

Large B‑cell lymphoma is a type of fast-growing cancer that starts in B cells, a kind of white blood cell that helps the body fight infection. For investors it matters because the condition drives demand for diagnostics, treatments and clinical trials; positive or negative trial results, regulatory decisions or new therapies can quickly change a biotech or drug maker’s revenue prospects, similar to how a breakthrough product can reshape a company’s future.

relapsed/refractory medical

"ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL)"

Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.

pivotal trial medical

"within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

registration statement regulatory

"except pursuant to an effective registration statement or an applicable exemption"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form s-3 regulatory

"investors have been granted customary resale Form S-3 registration rights"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. Not financial advice.

• Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel
• Smital Shah appointed Chief Financial and Business Officer
  
  

SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL) in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026.

“Smital’s deep expertise in navigating complex financial landscapes and her proven track record of strategic leadership in the biotechnology industry make her the ideal partner to guide Lyell’s financial strategy as we enter a transformative year of execution,” said Lynn Seely, M.D., President and CEO of Lyell. “The attainment of the second $50 million tranche of the private placement is evidence of Lyell’s continued advancement toward significant value inflection points. Smital’s insights will be invaluable in ensuring we remain well-capitalized and operationally disciplined to deliver on our mission of bringing next-generation cell therapies to patients with cancer.”

Closing of Additional $50 Million Equity Private Placement Following Achievement of Clinical Milestone for Ronde-cel
Under the terms of the securities purchase agreement for the July 2025 equity private placement of up to $100 million, and following the initial closing of $50 million, Lyell held the right to require investors to purchase an additional $50 million of common stock upon the achievement of a clinical milestone for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal clinical development for patients with LBCL. Following the successful achievement of this clinical milestone, Lyell exercised this right and the investors purchased these shares from Lyell at a purchase price per share of $25.61, resulting in gross proceeds of approximately $50 million, bringing the total equity private placement proceeds to approximately $100 million. With the closing of this additional tranche, Lyell expects its cash, cash equivalents and marketable securities to be sufficient to meet working capital and capital expenditure needs into the second quarter of 2027.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The investors have been granted customary resale Form S-3 registration rights for the shares of common stock issued to them in the financing.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Smital Shah Appointed Chief Financial and Business Officer
Ms. Shah joins Lyell with over two decades of extensive leadership experience spanning corporate finance, capital markets and strategic operations within the biopharmaceutical industry. Most recently, she operated as an independent Chief Financial Officer and Chief Business Officer consultant, providing strategic guidance to multiple life sciences organizations. From 2014 to 2022, Ms. Shah served as the Chief Business and Financial Officer at ProQR Therapeutics (Nasdaq: PRQR) where she was responsible for directing all business functions, including finance, communications, commercial strategy, business development and legal.

Prior to her tenure at ProQR, Ms. Shah managed multi-billion-dollar debt, cash and investment portfolios at Gilead Sciences, Inc. She developed financial expertise through her tenure as an investment banker at Leerink Partners and J.P. Morgan, where she focused on capital raising and complex strategic transactions across the biotechnology sector. She began her career in various research and development roles at Johnson & Johnson.

Ms. Shah served on the Board of Directors of Pliant Therapeutics until June 2025 and as a Board Member and Chair of the Audit Committee at Graphite Bio until its merger with LENZ Therapeutics in 2024. She holds a B.S. in Chemical Engineering from the University of Mumbai, an M.S. in Chemical Engineering from Virginia Tech, as well as an M.B.A. in Finance from the University of California, Berkeley, Haas School of Business.

About Lyell
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of Lyell’s addition to its leadership team, including the anticipated benefits of Ms. Shah’s financial expertise and insights; the expected use of proceeds from the private placement; Lyell’s expectation that its financial position and cash runway will meet working capital and capital expenditure needs into the second quarter of 2027; Lyell’s anticipated progress, business plans, business strategy and clinical trials; Lyell’s advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission (SEC) on November 12, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact:
Peter Tran
Senior Director, Finance
ptran@lyell.com

FAQ

How much did Lyell (LYEL) raise in the March 9, 2026 private placement tranche?

Lyell raised an additional $50 million in the March 9, 2026 tranche. According to the company, this follows a clinical milestone and brings total placement proceeds to approximately $100 million.

What price per share did investors pay in Lyell's (LYEL) additional financing tranche?

Investors purchased shares at $25.61 per share in the additional tranche. According to the company, that price produced gross proceeds of roughly $50 million for the closing.

How long will Lyell's (LYEL) cash last after the additional $50 million close?

Lyell expects cash, cash equivalents and marketable securities to fund operations into Q2 2027. According to the company, this projection covers working capital and capital expenditure needs through that period.

Why did Lyell (LYEL) close the extra $50 million tranche for ronde-cel?

Lyell exercised investor purchase rights after achieving a clinical milestone for rondecabtagene autoleucel in the PiNACLE trial. According to the company, the milestone triggered the option to require the additional $50 million purchase.

Who is Lyell's new Chief Financial and Business Officer and what is her background?

Smital Shah was appointed Chief Financial and Business Officer effective March 9, 2026. According to the company, she has two decades of finance and business leadership including prior roles at ProQR and Gilead.